載入中
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
前收盤價
US$2.62
+US$0.24 · +10.08%
盤中時間採用ET。市場資料可能有所延遲。
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
日內區間
目前US$2.62
52週區間
目前US$2.62
盤中時間採用ET。市場資料可能有所延遲。
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
日內區間
目前US$2.62
52週區間
目前US$2.62
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 139.7萬 USD | 150.5萬 USD | 118.4萬 USD | — | — |
| 毛利 | −139.7萬 USD | −150.5萬 USD | −118.4萬 USD | — | — |
| 研究與開發 | 7104.3萬 USD | 7647.8萬 USD | 6812.6萬 USD | 5407.7萬 USD | 2379.9萬 USD |
| 銷售、一般及管理費用 | 2256.9萬 USD | 2126.1萬 USD | 1664萬 USD | 1422.4萬 USD | 811萬 USD |
| 營業費用 | 9221.5萬 USD | 9623.4萬 USD | 8358.2萬 USD | 6830.1萬 USD | 2710.9萬 USD |
| 利息收入 | 401.7萬 USD | 714.2萬 USD | 640萬 USD | 279.3萬 USD | — |
| 折舊和攤銷 | 139.7萬 USD | 150.5萬 USD | 118.4萬 USD | 49.3萬 USD | 17.8萬 USD |
| 營業利益 | −9361.2萬 USD | −9773.9萬 USD | −8476.6萬 USD | −6830.1萬 USD | −2710.9萬 USD |
| 淨利 | −8965.5萬 USD | −8998.1萬 USD | −7862.6萬 USD | −6910.4萬 USD | −2728.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 52.67%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI421.13萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF156.08萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB117.04萬0.01%108.2億 USD0.44%US$206.49+3.00%
iShares Micro-Cap ETFIWC31.74萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM22萬0.19%1.17億 USD0.73%US$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC10.14萬—30.82億 USD0.25%US$69.98+0.03%
Dimensional - US Small Cap ETFDFAS5.28萬0.00%338.69億 USD0.31%US$78.35+0.32%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4.8萬0.00%61.81億 USD0.26%US$68.28+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Small Cap ETFDFASU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
